Domainex and Vipergen Partner to Accelerate Hit and Lead Discovery
Cambridge, UK & Copenhagen, Denmark – 4th September 2026 – Domainex, a leading integrated drug discovery services partner, and Vipergen, a pioneering DNA-encoded library (DEL) screening company, today announced a strategic collaboration to support lead discovery programmes across a range of disease targets.
Through the collaboration, clients can now access Vipergen’s DEL screening capabilities alongside Domainex’s expertise in assay development, biophysics, medicinal chemistry, and integrated discovery services – providing a seamless, end-to-end solution from hit identification to validated leads.
A first client case study has already shown the partnership in action: Vipergen’s DEL screening platform identified novel molecular glue hits, and Domainex independently confirmed them through complementary biophysics and assay development work.
“This collaboration expands the range of hit and lead discovery solutions available to our clients by combining Vipergen’s unique DEL screening technology with Domainex’s established fragment-based and high-throughput screening (HTS) approaches, as well as our assay development, biophysics, and medicinal chemistry expertise. Together, we can help partners identify, validate, and progress high-quality starting points for their drug discovery programmes,” said Dr Hayley French, CEO of Domainex.
“We are thrilled to partner with Domainex, whose broad and complementary drug discovery capabilities make them an ideal partner for Vipergen. This collaboration allows us to offer clients a truly integrated path from DEL screening hits to optimised leads – combining the unique advantages of our cell-based and in vitro DEL platforms with Domainex’s world-class assay and medicinal chemistry expertise,” said Dr Nils Hansen, CEO of Vipergen.
Together, the two companies provide a complementary suite of technologies and expertise designed to streamline the transition from hit identification to validated lead series, helping accelerate early-stage drug discovery programmes.
For further information, please contact:
Domainex
Vipergen
About Domainex:
Domainex is a leading, multi-award-winning, integrated medicines research service partner which provides tailored discovery solutions from target expression to the identification of pre-clinical candidates.
Our world-leading experts accelerate research projects by combining a problem-solving approach with cutting-edge technologies such as PureDiscTM and Direct-to-Biology. With deep expertise across a wide range of target classes and therapeutic areas, and a core focus on the hit identification and hit-to-lead stages, we deliver high-quality results that support confident, timely decision-making for our partners. Domainex operates from state-of-the-art facilities in Cambridge, UK.
Further information about Domainex and its award-winning lead discovery services can be found at www.domainex.co.uk.
About Vipergen ApS:
Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit https://www.vipergen.com.